SpectraScience awarded U.S. patent for methods and apparatus for evaluating image focus



Once believed to be important only for bone health, vitamin D is now seen as having a critical function in maintaining the immune system throughout life. The newly recognized disease risks associated with vitamin D deficiency are clearly documented in a report in the December issue (Volume 3, Number 4) of Breastfeeding Medicine, a peer-reviewed

Full Post: Research highlights recognized disease risks associated with vitamin D deficiency

SpectraScience, Inc. has announced that it has been awarded U.S. Patent number 7,469,160 for its methods and apparatus for evaluating image focus.

Jim Hitchin, SpectraScience’s CEO, commented, “This patent is another important addition to our expanding intellectual property portfolio.”

The invention provides methods of focusing an instrument for the acquisition of optical data from a tissue sample. It allows rapid focusing in a diagnostic procedure in which quick data acquisition is desirable. For example, the techniques allow a user to focus an optical instrument quickly enough to obtain data within an optimal window of time. In one version, a user focuses an optical instrument by aligning laser spots projected onto a tissue sample within rings that are superimposed at predetermined locations within the user’s visual field. The invention further allows automatic validation to detect whether the spots are sufficiently well-aligned.

Hitchin added, “Accurate data acquisition and fast focusing techniques are critical for earlier and more effective identification of normal, pre-cancerous or cancerous tissue. This invention will make our screening devices more useful to the physician and, more importantly, more effective for the patient. It allows the LUMA Cervical Imaging System to detect close to 30% more ASCUS/LSIL cervical cancer precursors than colposcopy alone, providing clinicians with a valuable tool in the fight against cervical cancer. In fact, a recent large-scale National Cancer Institute-sponsored clinical trial demonstrated that colposcopy failed to detect 33% of high-grade precancerous lesions in women referred with questionable Pap results.”

SpectraScience holds approximately 60 patents worldwide that have been issued or are pending for its WavSTAT(R) Optical Biopsy and LUMA(R) Cervical Imaging Systems. These non-invasive optical devices are used to diagnose tissue quickly to determine if it is normal, pre-cancerous, or cancerous. The WavSTAT and LUMA Systems are currently approved by the FDA for detecting pre-cancerous and cancerous tissue in the colon and cervix, respectively. An evaluation of the WavSTAT for detection of pre-cancers in the throat (”Barrett’s esophagus”) is being tested.

This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements involve risks and uncertainties that may cause SpectraScience’s actual results to differ materially from results discussed in forward-looking statements. Readers are urged to carefully review and consider the various disclosures made by SpectraScience in this news release, its most recent Form 10-K and in SpectraScience’s other reports filed with the Securities and Exchange Commission (”SEC”) that attempt to advise interested parties of the risks and factors that may affect SpectraScience’s business. These forward-looking statements are qualified in their entirety by the cautions and risk factors filed by SpectraScience in its annual report on Form 10-K and other documents.

http://www.spectrascience.com/

Link




As testing for high-risk types of the human papillomavirus (HPV) emerges as the gold standard in cervical cancer prevention, scientists are already researching how to determine even more precisely who is most likely to develop the disease and thus are in need of more immediate intervention. Speaking at the EUROGIN (European Research Organization on Genital

Full Post: Researchers say identifying women with HPV types 16, 18 and 45 could improve early intervention to stop cervical cancer



BD Diagnostics, a segment of BD (Becton, Dickinson and Company) has announced that it received U.S. Food and Drug Administration (FDA) Premarket Approval (PMA) for the BD FocalPoint(TM) GS Imaging System. This innovative new system is designed to enhance cervical cancer screening for cytology laboratories using the BD SurePath(TM) Pap test slides to detect evidence

Full Post: BD Diagnostics receives FDA approval for imaging system that enhances detection of cervical cancer



Spherix Incorporated reported that patient recruitment for its Phase 3 clinical trial of its potential type 2 diabetes drug, Naturlose, has begun in India. Expectations for India are to provide more than 300 patients spread across 35 sites for the pivotal Phase 3 trial. “Now that enrollment efforts are underway in India, we believe that

Full Post: Spherix starts patient recruitment in India for phase 3 diabetes trial



As a part of National Cervical Health Awareness Month, Acting Secretary of Health Everette James has reminded women of the importance of cervical cancer prevention and the need for pap tests. “Every January as we begin a new year, we want to remind all Pennsylvanians to do what they can to improve their overall health,”

Full Post: Women reminded yearly examinations best way to prevent cervical cancer



Many scientists like to discuss how each form of cancer is a distinct disease with its own causes and its own treatments. But researcher Hartmut “Hucky” Land, Ph.D., takes the opposite approach: He is hunting for the most basic rules that all cancers share to make good cells go bad. His unique, far-reaching effort to

Full Post: $2.7 million boosts effort to create the big view of cancer